2609 T3D2568 Ceftriaxone Ceftriaxone is only found in individuals that have used or taken this drug. It is a broad-spectrum cephalosporin antibiotic with a very long half-life and high penetrability to meninges, eyes and inner ears. [PubChem]Ceftriaxone works by inhibiting the mucopeptide synthesis in the bacterial cell wall. The beta-lactam moiety of Ceftriaxone binds to carboxypeptidases, endopeptidases, and transpeptidases in the bacterial cytoplasmic membrane. These enzymes are involved in cell-wall synthesis and cell division. By binding to these enzymes, Ceftriaxone results in the formation of of defective cell walls and cell death. 73384-59-5 5479530 C18H18N8O7S3 554.046060 Solid (MSDS, A308). >155°C 1.05e-01 g/L Inhalation; dermal or skin contact; ingestion; intravenous (MSDS, A308). Ceftriaxone works by inhibiting the mucopeptide synthesis in the bacterial cell wall. The beta-lactam moiety of Ceftriaxone binds to carboxypeptidases, endopeptidases, and transpeptidases in the bacterial cytoplasmic membrane. These enzymes are involved in cell-wall synthesis and cell division. By binding to these enzymes, Ceftriaxone results in the formation of of defective cell walls and cell death. Ceftriaxone is eliminated unchanged in the urine by glomerular filtration (60%) and bile (40%) (A633). Route of Elimination: Thirty-three percent to 67% of a ceftriaxone dose was excreted in the urine as unchanged drug and the remainder was secreted in the bile and ultimately found in the feces as microbiologically inactive compounds. Half Life: 5.8-8.7 hours LD50: >10 000 mg/kg (Oral, Rat) No indication of carcinogenicity to humans (not listed by IARC). For the treatment of the infections (respiratory, skin, soft tissue, UTI, ENT) caused by S. pneumoniae, H. influenzae, staphylococci, S. pyogenes (group A beta-hemolytic streptococci), E. coli, P. mirabilis, Klebsiella sp, coagulase-negative staph (A308). Some observed adverse reactions ( < 0.1%) include abdominal pain, agranulocytosis, allergic pneumonitis, anaphylaxis, basophilia, biliary lithiasis, bronchospasm, colitis, dyspepsia, epistaxis, flatulence, gallbladder sludge, glycosuria, hematuria, jaundice, leukocytosis, lymphocytosis, monocytosis, nephrolithiasis, palpitations, a decrease in the prothrombin time, renal precipitations, seizures, and serum sickness (RxList, A308). Abdominal pain. In the case of overdosage, drug concentration would not be reduced by hemodialysis or peritoneal dialysis. There is no specific antidote. Treatment of overdosage should be symptomatic (RxList, A308). 2009-07-05T03:20:59Z 2026-05-14T16:58:47Z Ceftriaxone C06683 29007 Ceftriaxone DB01212 true [H][C@]12SCC(CSC3=NC(=O)C(=O)NN3C)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O C18H18N8O7S3 InChI=1S/C18H18N8O7S3/c1-25-18(22-12(28)13(29)23-25)36-4-6-3-34-15-9(14(30)26(15)10(6)16(31)32)21-11(27)8(24-33-2)7-5-35-17(19)20-7/h5,9,15H,3-4H2,1-2H3,(H2,19,20)(H,21,27)(H,23,29)(H,31,32)/b24-8-/t9-,15-/m1/s1 VAAUVRVFOQPIGI-SPQHTLEESA-N 554.58 554.04605704 Exogenous Solid -1.7 HMDB15343 CHEMBL161 4514885 <p>Monguzzi Riccardo, Menaspace Silvano, Anzaghi Piergiorgio, &#8220;Process for the preparation of ceftriaxone.&#8221; U.S. Patent US5026843, issued November, 1984.</p> CHEM002094 DTXSID0022773 NS00007027 (6R,7R)-7-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetamido]-3-{[(2-methyl-5,6-dioxo-1,2,5,6-tetrahydro-1,2,4-triazin-3-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid 208.98000000000002 128.46669999999995 51.46712614184927 8 12 4 3.1880236213884396 4.166923225318286 -1 4 -0.01 -3.72 1.05e-01 g/l